[go: up one dir, main page]

WO2002000878A3 - Dynamine mitochondriale humaine msp1, ses isoformes msp1-x, et leur utilisation en therapeutique - Google Patents

Dynamine mitochondriale humaine msp1, ses isoformes msp1-x, et leur utilisation en therapeutique Download PDF

Info

Publication number
WO2002000878A3
WO2002000878A3 PCT/FR2001/001999 FR0101999W WO0200878A3 WO 2002000878 A3 WO2002000878 A3 WO 2002000878A3 FR 0101999 W FR0101999 W FR 0101999W WO 0200878 A3 WO0200878 A3 WO 0200878A3
Authority
WO
WIPO (PCT)
Prior art keywords
msp1
isoforms
human
concerns
therapeutic use
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2001/001999
Other languages
English (en)
Other versions
WO2002000878A2 (fr
Inventor
Guy Lenaers
Bernard Ducommun
Christian Hamel
Cecile Delettre
Pascale Belenguer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Toulouse
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Toulouse III Paul Sabatier
Universite de Toulouse
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Universite Toulouse III Paul Sabatier, Universite de Toulouse filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Publication of WO2002000878A2 publication Critical patent/WO2002000878A2/fr
Anticipated expiration legal-status Critical
Publication of WO2002000878A3 publication Critical patent/WO2002000878A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4722—G-proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention a pour objet une protéine humaine appartenant à la famille des dynamines, appelée MSP1, et ses 7 isoformes MSP1-X, dont les mutations sont en particulier responsables de l'atrophie optique dominante. La présente invention concerne également les séquences nucléotidiques codant ladite protéine, ses isoformes et leurs formes mutées, les vecteurs capables d'exprimer ladite protéine et ses isoformes ou leurs formes mutées, dans tout type de cellules hôtes, ainsi que les cellules transformées par lesdits vecteurs et les procédés les utilisant. L'invention a enfin pour objet des procédés d'identification de composés biologiques ou pharmacologiques modulant l'activité de la protéine d'identification de composés biologiques ou pharmacologiques modulant l'activité de la protéine et de ses isoformes selon l'invention et l'utilisation desdits composés pour la recherche et la fabrication de substances actives utiles en thérapie, en particulier pour la mise au point d'un traitement de l'atrophie optique dominante.
PCT/FR2001/001999 2000-06-26 2001-06-25 Dynamine mitochondriale humaine msp1, ses isoformes msp1-x, et leur utilisation en therapeutique Ceased WO2002000878A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0008140A FR2810673B1 (fr) 2000-06-26 2000-06-26 Dynamine mitochondriale humaine msp1 et son utilisation en therapeutique
FR00/08140 2000-06-26

Publications (2)

Publication Number Publication Date
WO2002000878A2 WO2002000878A2 (fr) 2002-01-03
WO2002000878A3 true WO2002000878A3 (fr) 2003-04-24

Family

ID=8851656

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2001/001999 Ceased WO2002000878A2 (fr) 2000-06-26 2001-06-25 Dynamine mitochondriale humaine msp1, ses isoformes msp1-x, et leur utilisation en therapeutique

Country Status (2)

Country Link
FR (1) FR2810673B1 (fr)
WO (1) WO2002000878A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0023555D0 (en) * 2000-09-26 2000-11-08 Inst Of Ophthalmology Improvements in and relating to treatments for eye disease
AU2003214048A1 (en) * 2002-01-25 2003-09-02 Develogen Aktiengesellschaft Fur Entwicklungsbiologische Forschung Proteins involved in the regulation of energy homeostasis and organelle metabolism
WO2007056435A2 (fr) 2005-11-08 2007-05-18 The General Hospital Corporation Maladies mediees par la dynamine et procedes et produits associes
US9144594B2 (en) 2005-11-08 2015-09-29 University Of Miami Cathepsin L mediated diseases and associated methods and products
WO2007134818A2 (fr) 2006-05-18 2007-11-29 Univ Muenchen L Maximilians Procédé pour diagnostiquer un dysfonctionnement mitochondrial
CN111518897A (zh) * 2019-02-01 2020-08-11 中国科学院广州生物医药与健康研究院 分子标志物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001053312A1 (fr) * 1999-12-23 2001-07-26 Hyseq, Inc. Nouveaux acides nucleiques et polypeptides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001053312A1 (fr) * 1999-12-23 2001-07-26 Hyseq, Inc. Nouveaux acides nucleiques et polypeptides

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ALEXANDER C ET AL: "OPA1, ENCODING A DYNAMIN-RELATED GTPASE, IS MUTATED IN AUTOSOMAL DOMINANT OPTIC ATROPHY LINKED TO CHROMOSOME 3Q28", NATURE GENETICS, NATURE AMERICA, NEW YORK, US, vol. 26, no. 2, October 2000 (2000-10-01), pages 211 - 215, XP000993212, ISSN: 1061-4036 *
BROWN JEREMIAH JR ET AL: "Clinical and genetic analysis of a family affected with dominant optic atrophy (OPA1).", ARCHIVES OF OPHTHALMOLOGY, vol. 115, no. 1, 1997, pages 95 - 99, XP000993189, ISSN: 0003-9950 *
DATABASE EMBL [online] 10 April 1998 (1998-04-10), OHARA O ET AL: "Homo sapiens mRNA for KIAA0567 protein, partial cds.", XP002166490, Database accession no. AB011139 *
DATABASE EMBL [online] 22 October 2001 (2001-10-22), TANG Y T ET AL: "Human polynucleotide SEQ ID NO 731.", XP002203707, Database accession no. AAI58528 *
DATABASE EMBL [online] 22 October 2001 (2001-10-22), TANG Y T ET AL: "Human polypeptide SEQ ID NO 2517.", XP002203708, Database accession no. AAM39372 *
DELETTRE CECILE ET AL: "Nuclear gene OPA1, encoding a mitochondrial dynamin-related protein, is mutated in dominant optic atrophy.", NATURE GENETICS, vol. 26, no. 2, October 2000 (2000-10-01), pages 207 - 210, XP000993218, ISSN: 1061-4036 *
PESCH U E A ET AL: "Genomic structure of a retinal expressed candidate gene for dominant optic atrophy (Kjer type).", AMERICAN JOURNAL OF HUMAN GENETICS, vol. 65, no. 4, October 1999 (1999-10-01), 49th Annual Meeting of the American Society of Human Genetics;San Francisco, California, USA; October 19-23, 1999, pages A378, XP000993287, ISSN: 0002-9297 *
PESCH ULRIKE E A ET AL: "OPA1 mutations in patients with autosomal dominant optic atrophy and evidence for semi-dominant inheritance.", HUMAN MOLECULAR GENETICS, vol. 10, no. 13, 2001, pages 1359 - 1368, XP002203706, ISSN: 0964-6906 *
VAN DER BLIEK ALEXANDER M: "Functional diversity in the dynamin family.", TRENDS IN CELL BIOLOGY, vol. 9, no. 3, March 1999 (1999-03-01), pages 96 - 102, XP002203705, ISSN: 0962-8924 *

Also Published As

Publication number Publication date
WO2002000878A2 (fr) 2002-01-03
FR2810673B1 (fr) 2004-10-08
FR2810673A1 (fr) 2001-12-28

Similar Documents

Publication Publication Date Title
DE68929043D1 (de) Für androgen-rezeptor-protein kodierende dna
AU2001254624A1 (en) Human coagulation factor vii variants
SI1641483T1 (sl) Fuzijski proteini
AU1724795A (en) Human tissue inhibitor of metalloproteinase-4
WO1995025171A3 (fr) Sequences d'adn pour metalloproteases matricielles, leur production et leur utilisation
NO960309L (no) Agonister og antagonister for humaninterleukin-10
WO2004074486A3 (fr) Proteines de fusion de muteines d'interferon-alpha aux proprietes ameliorees
DE68926679D1 (de) Physiologisch aktives polypeptid, rekombinantes plasmid, rekombinante mikrobielle zellen, medizinisches präparat sowie verfahren zur gewinnung des gereinigten polypeptids
AU6745287A (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors, biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
NO20014537D0 (no) AKT-nukleinsyrer, -polypeptider og anvendelse av disse
WO2002000878A3 (fr) Dynamine mitochondriale humaine msp1, ses isoformes msp1-x, et leur utilisation en therapeutique
EP1281763A3 (fr) FACTEUR DE TRANSCRIPTION "Early growth response-1" (EGR-1)
ATE291586T1 (de) Humanes antibiotisches protein
WO2000008157A3 (fr) Genes humains transporteurs d'anions atnov
HUP9801681A2 (hu) Mutáns proteinek
DK1283214T3 (da) Hidtil ukendte kollektiner
AU5327198A (en) Nucleotide sequence coding for a flavin-containing monooxygenase, corresponding protein and their applications in the fields of diagnosis and therapy
AU9743698A (en) Allelic variant of human stat3
HUP0300813A2 (hu) Gének, fehérjék és alkalmazásuk
WO2002012336A3 (fr) THERAPEUTIQUES DU TGF-β, COMPOSITIONS ET PROCEDES D'UTILISATION
AU2003258550A1 (en) Splicing-variant of the human p53 protein and use thereof in the production of pharmaceutical preparations for treating tumoural diseases
WO2003018804A1 (fr) Proteines pouvant commander la migration cellulaire et la mort cellulaire
WO2000068385A3 (fr) Nouveaux acides nucleiques et proteines a activite d'hormone de croissance
WO2000022097A3 (fr) Precurseurs mesenchymateux de sang peripherique
AU2002222307A1 (en) Proteins, genes and their use for diagnosis and treatment of cardiac response

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase